NASH Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2021 - 2026
NASH Market Report
Overview
NASH Market is projected to reach revenue of $5.6 billion by 2024, and is estimated to grow at a CAGR of 55% during the forecast period 2019-2024. NASH (Non-Alcoholic SteatoHepatitis) is a severe form of liver disease that can further lead to fibrosis, cirrhosis and cancer. Changes in lifestyle have contributed to the rising prevalence of NASH disease. The factors such as increase of diabetic and obese population are also driving the growth of the NASH market. Other secondary disorders such as lysosomal acid lipase deficiency, can also lead to liver cirrhosis and ultimately result in NASH.
Key Takeaways
NASH Market is estimated to grow at a CAGR of 55% owing to the rising prevalence of diabetes and obesity. The NASH market size in 2018 is $0.41 billion.
North America held the largest market share terms of revenue owing to its research in healthcare sector. A large population in North America are also affected by NASH providing a large market here. The NASH market share for North America in 2018 was 42%.
The increase in the number of patients affected by NASH has boosted the need for NASH diagnosis and treatment. The increase in investments by companies for research and clinical studies has also contributed to market growth. However, regulatory approvals are hard to get and thus there are no approved drugs in the market for NASH.
Type - Segment Analysis
Demand for non-invasive and cost-efficient diagnostic tools for NASH techniques such as biomarker tests has been increasing. This is set to drive the demand for NASH biomarkers in the coming years. Serum biomarkers had major share by revenue, due to its high diagnostic efficiency. Serum biomarkers have the ability to distinguish simple steatosis from NASH and thus provide efficient result. Thus it will reduce the reliance on liver biopsy.
End-Use - Segment Analysis
The end-use segment is dominated by the Pharmaceutical CRO (Contract Research Organization) industry, owing to the ample funding for research activities being carried out for developing NASH drug. The ongoing clinical trials by CROs and pharmaceutical manufacturers can be contribute to the market growth. The Pharmaceutical CRO segment is estimated to grow with a CAGR of 52.8% during the forecast period.
Geography - Segment Analysis
North America is estimated to hold largest share in NASH market in 2018 and is projected to maintain its dominance during the forecast period. NASH prevalence in the U.S. is 12%, according to The NASH Education Program. The disease is one of the leading cause of liver cirrhosis in the U.S. Along with this people of U.S. are also affected by diabetes and obesity which are responsible for NASH. Government initiatives favoring drug development and funding for R&D is high in the U.S, thereby fueling the market growth.
Comments
Post a Comment